Exegenesis Bio has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for gene therapy EXG102-031.
19 Jan 2023
20 Jul 2022
Avista Therapeutics has announced partnership with Roche to develop new AAV gene therapy vectors for the eyes.
13 Apr 2022
Aurion Biotech has raised $120m from biotech and ophthalmology investors to progress its cell therapy programme for corneal edema secondary to endothelial dysfunction.